Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013

Vaccine

Volumn 32, Issue 22, 2014, Pages 2553-2562

  Guevara, Marcela ^a,b   Ezpeleta, Carmen ^c   Gil Setas, Alberto ^c   Torroba, Luis ^c   Beristain, Xabier ^c   Aguinaga, Aitziber ^d   García Irure, José Javier ^e   Navascués, Ana ^f   García Cenoz, Manuel ^a,b   Castilla, Jesús ^a,b   Chamorro, Judith ^c   Gabari, Mercedes ^c   Artajo, Pilar ^c   Peña, Luz ^c   Bernaola, Enrique ^c   Herranz, Mercedes ^c   Clerigué, Nuria ^c   Kutz, María ^c   Polo, Isabel ^c   Martín, Carmen ^c   Mazón, Ana ^c   Leiva, José ^d   Núñez Córdoba, Jorge M ^d   Ortega, Maite ^g   Torres, Montse ^g   Lameiro, Francisco ^f   Barricarte, Aurelio ^a   Irisarri, Fátima ^a   Arriazu, Maite ^a   Martínez Baz, Iván ^a   more..

^a INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL GARCÍA ORCOYEN   (Spain)

^g Anatomía Patológica del Hospital Reina Sofía de Tudela   (Bulgaria)

Author keywords

Impact; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Public health surveillance; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE SEVERITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

IMPACT; INVASIVE PNEUMOCOCCAL DISEASE; PNEUMOCOCCAL CONJUGATE VACCINE; PUBLIC HEALTH SURVEILLANCE; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SENTINEL SURVEILLANCE; SPAIN; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84898548365     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.054     Document Type: Article

References (37)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
2. Said M.A., Johnson H.L., Nonyane B.A., Deloria-Knoll M., O'Brien K.L., Andreo F., et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013, 8:e60273.
3. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009, 6:e1000081.
4. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect 2010, 61:114-124.
5. Lucero M.G., Dulalia V.E., Nillos L.T., Williams G., Parreño R.A., Nohynek H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009, 7:CD004977.
6. De Wals P., Lefebvre B., Defay F., Deceuninck G., Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 2012, 30:6416-6420.
7. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:9127-9131.
8. Fitzwater S.P., Chandran A., Santosham M., Johnson H.L. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012, 31:501-508.
9. Hausdorff W.P., Dagan R., Beckers F., Schuerman L. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 2009, 27:7257-7269.
10. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
11. Kellner J.D., Vanderkooi O.G., MacDonald J., Church D.L., Tyrrell G.J., Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009, 49:205-212.
12. Guevara M., Barricarte A., Gil-Setas A., García-Irure J.J., Beristain X., Torroba L., et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009, 15:1013-1019.
13. Muñoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46:174-182.
14. Hanquet G., Lernout T., Vergison A., Verhaegen J., Kissling E., Tuerlinckx D., et al. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine 2011, 29:2856-2864.
15. Lepoutre A., Varon E., Georges S., Gutmann L., Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 2008, 13. pii:18962.
16. Rückinger S., van der Linden M., Reinert R.R., von Kries R., Burckhardt F., Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009, 27:4136-4141.
17. Moreno-Pérez D., Alvarez García F.J., Aristegui Fernández J., Barrio Corrales F., Cilleruelo Ortega M.J., Corretger Rauet J.M., et al. Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations. An Pediatr (Barc) 2012, 76. 43.e1-23.
18. Barricarte A., Castilla J., Gil-Setas A., Torroba L., Navarro-Alonso J.A., Irisarri F., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 2007, 44:1436-1441.
19. Domínguez A., Ciruela P., García-García J.J., Moraga F., de Sevilla M.F., Selva L., et al. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. Vaccine 2011, 29:9020-9025.
20. Kaplan S.L., Barson W.J., Lin P.L., Romero J.R., Bradley J.S., Tan T.Q., et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013, 32:203-207.
21. Picazo J., Ruiz-Contreras J., Casado-Flores J., Negreira S., García-de-Miguel M.J., Hernández-Sampelayo T., et al. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Clin Vaccine Immunol 2013, 20:1524-1530.
22. Rudnick W., Liu Z., Shigayeva A., Low D.E., Green K., Plevneshi A., et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. Vaccine 2013, 31:5863-5871.
23. Singleton R., Wenger J., Klejka J.A., Bulkow L.R., Thompson A., Sarkozy D., et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J 2013, 32:257-263.
24. Steens A., Bergsaker M.A., Aaberge I.S., Rønning K., Vestrheim D.F. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013, 31:6232-6238.
25. Aguilar I., Reyes M., Martinez-Baz I., Guevara M., Albeniz E., Belza M., et al. Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain. Euro Surveill 2012, 17. pii: 20154.
26. Fenoll A., Jado I., Vicioso D., Casal J. Dot blot assay for the serotyping of pneumococci. J Clin Microbiol 1997, 35:764-766.
27. Davis S.M., Deloria-Knoll M., Kassa H.T., O'Brien K.L. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 2013, 32:133-145.
28. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
29. Simonsen L., Taylor R.J., Young-Xu Y., Haber M., May L., Klugman K.P. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011, 2:e00309-e310.
30. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.
31. Wenger J.D., Zulz T., Bruden D., Singleton R., Bruce M.G., Bulkow L., et al. Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr Infect Dis J 2010, 29:251-256.
32. Flasche S., Van Hoek A.J., Sheasby E., Waight P., Andrews N., Sheppard C., et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 2011, 8:e1001017.
33. Domenech A., Ardanuy C., Tercero A., García-Somoza D., Santos S., Liñares J. Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009-12): comparison with 2001-04 and 2005-08 periods. J Antimicrob Chemother 2014, 69:932-939.
34. Rolo D., Fenoll A., Ardanuy C., Calatayud L., Cubero M., de la Campa A.G., et al. Trends of invasive serotype 6C pneumococci in Spain: emergence of a new lineage. J Antimicrob Chemother 2011, 66:1712-1718.
35. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051.
36. Luján M., Burgos J., Gallego M., Falcó V., Bermudo G., Planes A., et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin Infect Dis 2013, 57:1722-1730.
37. Black S. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Pediatr Infect Dis J 2010, 29:301-303.